EMEA-003456-PIP01-23 - paediatric investigation plan

2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol
PIPHuman

Key facts

Active Substance
2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0427/2023
PIP number
EMEA-003456-PIP01-23
Pharmaceutical form(s)
All pharmaceutical forms
Condition(s) / indication(s)
Treatment of myelofibrosis
Route(s) of administration
All routes of administration
Contact for public enquiries

Bristol-Myers Squibb Pharma EEIG

Email: medical.information@bms.com
Tel. +44 1423 533 610

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page